Glucagon like Peptide 1 News and Research

RSS

Novel member of a class of anti-diabetes drugs could help treat muscle wasting disease

Inflammatory myopathies can be challenging to treat, but a new study reports encouraging findings for patients with these debilitating conditions. Researchers from Japan have found that a novel member of a class of anti-diabetes drugs could be the key to treating patients with muscle wasting disease.

18 Aug 2022

A low-energy, high FODMAP diet in prediabetes and diabetes?

Researchers summarize the available knowledge on FODMAPs and suggest that they can play a role in the prevention and treatment of diabetes.

10 Aug 2022

Researchers assess Alzheimer's disease risk and anti-diabetic drugs

In a new study, researchers assessed the genetic variation among targets of Alzheimer's disease risk and anti-diabetic drugs.

3 Aug 2022

Diabetes patients on Medicare Advantage plans less likely to be prescribed newer, more expensive medicines

While patients with diabetes on Medicare Advantage plans are more likely to receive preventive treatments, they were less likely to be prescribed newer, more expensive medications and were more likely to have higher blood pressure and worse blood glucose control than patients on Medicare Fee-For-Service plans, according to a new study led by a University of Pittsburgh School of Medicine physician-scientist.

7 Jul 2022

Researchers discover why patients suffering with hypertension also have diabetes

The long-standing enigma of why so many patients suffering with high blood pressure (known as hypertension) also have diabetes (high blood sugar) has finally been cracked by an international team led by the universities of Bristol, UK, and Auckland, New Zealand.

1 Feb 2022

DPP4 protein: The connection between severe COVID-19 and diabetes

Researchers explore the relationship between DPP4 and diabetes targets in the management of COVID-19.

17 Jan 2022

New study shows inequities in the use of heart disease-protective diabetes drug

A medication typically used for treating diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RA), could also be used to prevent cardiovascular disease and major cardiovascular events, but a new study showed inequities in its use based on race, ethnicity, and socioeconomic status.

17 Dec 2021

Drug treatment decreases risk for severe COVID-19 outcomes in patients with Type 2 diabetes

A type of drug already used to treat obesity and Type 2 diabetes, when taken six months prior to the diagnosis of COVID-19, was associated with a decreased risk of hospitalization, respiratory complications and death in COVID-19 patients with Type 2 diabetes, according to researchers at Penn State College of Medicine.

27 Sep 2021

Weight loss drug Wegovy approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Wegovy (semaglutide) injection (2.4 mg once weekly) as a chronic weight management treatment in obese or overweight adults with a weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), when used along with calorie restriction and physical activity. Wegovy, is a more potent version of Novo Nordisk's diabetes drug semaglutide.

4 Jun 2021

HCAs are a promising risk indicator of type 2 diabetes

A series of studies led by researchers from Hong Kong Baptist University have revealed that hyocholic acid and its derivatives (collectively known as HCAs), a component of bile acids that facilitate fat digestion, are a promising risk indicator of type 2 diabetes.

1 Apr 2021

Can metformin reduce mortality in diabetic individuals with severe COVID-19?

A new study by researchers in China and the U.S. describes a round-up of the effects of commonly used hypoglycemic drugs on the outcomes of COVID-19 in diabetic patients.

1 Feb 2021

New drug combination improves blood glucose control and weight loss in mice

Scientists have shown that adding an experimental cancer drug to a widely used diabetes treatment improves blood glucose control and weight loss in mice, according to a study published today in eLife.

22 Dec 2020

Research uncovers novel anti-craving mechanism to treat cocaine relapse

Cocaine continues to be one of the most commonly abused illicit drugs in the United States. Pre-clinical literature suggests that targeting glucagon-like peptide-1 receptors (GLP-1Rs) in the brain may represent a novel approach to treating cocaine use disorder.

7 Dec 2020

Drug combo for Type 2 diabetes continues to stay effective after two years of treatment

Patients with Type 2 diabetes often take metformin as first-line therapy to help stabilize their blood glucose.

2 Nov 2020

Study shows fatty liver disease is a significant risk factor for COVID-19 hospitalization

A recent observational study by US researchers reveals that individuals with non-alcoholic fatty liver disease and steatohepatitis have increased odds of hospitalization due to coronavirus disease (COVID-19); conversely, metabolic surgery was found to be protective against the admission of infected individuals. The study is currently available on the medRxiv* preprint server.

3 Sep 2020

New approach to combination drug design could be applied to disease therapies beyond diabetes

Biomedical engineers at Duke University have shown that the efficacy of a two-pronged type 2 diabetes treatment increases when the drugs are linked by a heat-sensitive tether rather than simply concurrently administered.

27 Aug 2020

Chemist develops new drug to treat type 2 diabetes without undesired side effects

Syracuse University chemistry professor Dr. Robert P. Doyle has developed a new drug lead to treat type 2 diabetes in millions of patients who are seeking to better control their blood sugar without the common side effects of nausea, vomiting, and in select cases, undesired weight loss.

23 Jun 2020